Vet Futures, the joint initiative by the RCVS and BVA to stimulate debate about the future of the profession, has opened a new discussion about whether VAT on vet fees for pets should be dropped.
The discussion has been opened by this month's Vet Futures guest blogger, Stuart Winter, the Sunday Express small animal columnist and a campaigner to end VAT on pet fees.
Stuart argues that owning a pet is not a luxury to be taxed when they need medical intervention, because owning a companion improves the health and wellbeing of its owner.
He writes that removing VAT on veterinary fees for domestic animals, or at least reducing it to five pence in the pound, would improve the nation's animal welfare. It would allow low-income families to seek medical attention earlier, he argues, while allowing more owners to afford and take out pet insurance.
He says that shifting Government thinking on the subject might be a Herculean task, but that doesn't mean we shouldn't campaign for its removal. "No Chancellor delights in losing revenue. Treating, curing and caring for sick and injured animals is nothing more than a service and services are ripe to be harvested.
"It is time for a counter argument. Pet ownership is not a luxury. It is more than a privilege. Is it not a human right? Welcoming animals into our lives makes our lives more fulfilled and more civilised."
To tie in with the discussion, Vet Futures is inviting vets to take part in a poll which asks: "Would you agree that VAT should no longer be levelled on vet fees?"
The College is encouraging members of the veterinary team and the public to take part in the poll so that it can generate debate on the issue of VAT and better understand the full consequences if it was removed.
January's poll asked members of the profession if they could recognise the signs of mental ill-health in a colleague. Reassuringly, just over half (58%) of the 65 respondents said they would be able to recognise the signs, although that leaves 40% who would not feel comfortable in their ability to do so.
To read Stuart Winter's blog, contribute to the discussion and vote in the poll, visit www.vetfutures.org.uk
The product was one of eight NSAIDS that had been suspended following a European ruling that an excipient, diethanolamine, may pose a risk to human health.
Allevinix is licensed for both intravenous (I/V) and intramuscular (I/M) administration over one to three days in cattle. It has a dose rate of 4ml per 100kg liveweight in cattle, and milk withdrawal times of 24 hours after I/V injection and 36 hours after I/M injection.
Ceva says Allevinix reaches peak plasma levels (CMax) approximately 30 minutes following I/M injection. It is available in 100ml and 250ml vials.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: "Allevinix is the only flunixin licensed for both intramuscular and intravenous administration in cattle and provides both vets and farmers with a cost-effective, fast-acting and versatile NSAID that is a useful addition to the range of NSAID options available."
For more information, contact your Ceva account manager, email cevauk@ceva.com or call the ruminant marketing department at Ceva on 01494 781510.
The tool is available to all practices, free of charge.
The downloadable and printable guide chart, which has been created by a number of specialists, will help veterinary surgeons, nurses and receptionists to identify urgent, potentially urgent, non-urgent and delayable cases to help limited veterinary resources be used to best efficiency without compromise to animal health or welfare.
The chart, which can be printed and put on a practice wall or referred to as a webpage via a mobile phone or tablet, has a number of supporting resources produced by the same specialists.
Sue Paterson, BSAVA President, said: “During these exceptional and worrying times veterinary surgeons need as much practical help and support as possible.
"We are hugely grateful for the indefatigable support of an enthusiastic group of volunteers who have rapidly produced this triage tool, which we are now able to share. It should enable patient queries to be processed, reliably and efficiently, allowing for emergency patients to be seen as a matter of urgency, within the current government and RCVS guidelines."
The triage tool is free to download and share: https://www.bsava.com/TriageTool
BSAVA is working on a number of other initiatives to support veterinary professionals during the current crisis, including new guidance on obtaining consent remotely for veterinary treatment. for more information, visit: https://www.bsava.com/adviceforCOVID19
Jonathan Hill (UK Country Manager) said: “I’m delighted to announce that TVM UK is changing its name to Dômes Pharma.
"This will align with the other operating companies within the group.
"TVM UK has always been owned by the Dômes Pharma group, and since the start of our journey in the UK market we have been synonymous with expertise and outstanding levels of customer service in selected speciality segments of the animal health market and this won’t change.”
“Under the Dômes Pharma name we will continue to build and grow on this very strong foundation.
"I’m looking forward to working with the entire Dômes Pharma team as we increase our presence as a leading specialty pharmaceutical company, bringing our ethos to new speciality segments with innovative products and solutions for vets in the UK.
"Dômes Pharma remains a family-owned business, and the culture of the company really reflects this and we live by our values of kindness, boldness and responsibility.” https://www.domespharma.com https://www.tvm-uk.com
In the study titled “Safety of early postoperative hydrotherapy in dogs undergoing thoracolumbar hemilaminectomy”, the medical records of a single referral hospital in Sweden were retrospectively reviewed to identify dogs that had been treated with hemilaminectomy for acute or chronic thoracolumbar IVDE and had commenced hydrotherapy within five days after surgery.
Information collected from the medical records included signalment, presenting clinical signs, severity of neurological signs, initiation and duration of hydrotherapy, postoperative complications and follow-up.
Postoperative complications were considered major if there was a need for hospitalisation, surgery or if the dog died or was euthanised as a direct consequence of the complication.
A complication was deemed minor if outpatient medical treatment was sufficient to rectify it.
A total of 83 dogs were included in the study.
Hydrotherapy was started within a mean of 2.7 (one to five) days after surgery and consisted of swimming without underwater treadmill (UWTM) in dogs with severe paraparesis or paraplegia.
With neurological improvement, and when supported ambulation was possible, UWTM was initiated.
Ninety-six percent of the dogs used swimming as postoperative hydrotherapy, starting with a mean of 2.7 days after surgery, fifty-seven percent of the dogs used UWTM as the postoperative hydrotherapy, starting with a mean of 13 days after surgery.
Forty-five percent of dogs used both hydrotherapeutic modalities.
Dr Abtin Morjarradi, corresponding author for the paper, said: “A total of 10 minor complications were recorded during the study period, including surgical site infection (SSI) (n=5), diarrhoea (n=4) and urinary tract infection (n=1).
Major complications were recorded in 26 dogs during the study period and included euthanasia (n=13), acute dermatitis (n=1), spinal abscess (n=1) and disc extrusion (n=1).
Reasons for euthanasia were urinary incontinence (n=5), lack of neurological improvement (n=2), clinical suspicion of progressive myelomalacia (PMM) (n=2), persistent pain (n=1), aggression (n=1) and widespread cellulitis with an abscess caudal to the right stifle without known cause (n=1).”
Abtin added: “Follow-up visits for 71 dogs were performed at a mean of 15.3 (9 to 30) days, and 68 dogs at a mean of 45.9 (30 to 111) days, after surgery.
"At the first follow-up visit 68% of the dogs were ambulatory with Modified Frankel Score (MFS) 4 or higher.
"At the last follow-up visit 97% of the dogs were ambulatory with MFS 4 or higher, with 34% demonstrating normal neurological function. None of these dogs deteriorated after the initiation time of hydrotherapy.”
Nicola Di Girolamo, Editor of JSAP, said: “Whilst previous studies indicate that early rehabilitation may be beneficial after acute spinal cord injury, the optimal timing to start hydrotherapy is unclear.
“Despite a high number of complications being recorded in the present study, it is not clear how many of these complications were directly related to the initiation time of hydrotherapy and therefore further research is required.”
The full article can be found in the December issue of the Journal of Small Animal Practice: https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13412.
Reference
Bayer Animal Health has launched Renalzin®, a feed additive for the management of Chronic Renal Disease (CRD), the leading cause of morbidity and mortality, especially in older cats1.
One-third of all cats over 15 years of age have CRD2, but the disease often remains undetected until the cat suddenly falls ill, by which stage 85% of kidney function may have already been lost3. The clinical signs are often subtle and non-specific, and diagnosis is complicated by the fact that changes in laboratory values occur relatively late in the disease.
Dr. Dennis Chew, specialist in veterinary urology and nephrology at the Ohio State University, said: "Most veterinary surgeons understand that CRD affects many cats, especially as they age, and is a leading cause of death. CRD is difficult to identify in early stages - early intervention with treatment can prevent progression of CRD to those with more serious kidney deficits. Restriction of dietary phosphorus intake is known to be a pivotal beneficial step in the stabilisation of CRD. Renalzin is a paste specifically formulated for cats that prevents dietary phosphate absorption across the intestine - a beneficial effect is gained when added to the cat's normal diet or to a veterinary renal diet".
The main ingredient of Renalzin is Bayer-registered Lantharenol® (lanthanum carbonate), a phosphate binder which binds to dietary phosphate within the gastrointestinal tract. According to the company, this renders it indigestible and thereby eases the burden on the already damaged kidneys.
Renalzin contains two additional ingredients - kaolin and vitamin E. Kaolin is a toxin binder which helps to reduce the absorption of toxins from the gastrointestinal tract. Vitamin E is known to reduce free radicals, improving immunity and protecting the integrity of cell membranes.
Bayer says that clinical studies demonstrate that Renalzin significantly increases faecal elimination and decreases urinary excretion of phosphorus 5. The product also decreases phosphate digestibility (absorption) in cats that are on both high and lower phosphate diets6. In addition, studies have shown that Renalzin causes a decrease in serum phosphate levels in cats with standard maintenance diets non-restricted in phosphorus7. Finally, a clinical trial in feline CRD patients revealed that taking Renalzin resulted in improvements in general clinical examination parameters as assessed by their veterinary surgeons over a two month period in cats on a normal diet7.
Renalzin comes in a pump applicator. One pump action provides 1 ml, with 2 ml being the recommended daily dose applied to and/or mixed with the cat's food. Having a neutral taste and being odourless, Renalzin® does not change the flavour of the cat's food and is flexible for clients to use as it can be given once or twice daily depending on the cat's feeding pattern.
References1 Lulich JP, O'Brien TD, Osbourne CA, Polzin DJ. Feline renal failure: questions, answers, questions. Cd Cont Ed Pract Vet 1992, 14(2): 127 - 151.2 Polzin DJ, Osbourne CA, Adams LG, Lulich JP. Medical management of feline chronic renal failure. In, Bonagura JD, Kirk RW (eds). Current Veterinarian Therapy X1. Philadelphia, PA, Saunders, 1992: 848-853.3 Grauer GF. Early detection of renal damage and disease in dogs and cats. Vet Clin Small Animal 2005, 35: 581-596.4 http://en.wikipedia.org/wiki/Lanthanum_carbonate.5 Schmidt B et al Bay 78-1887, J Vet Pharmacol Therap 2006, 29 (Suppl 1): 206-2076 Schmidt B, Spiecker-Hauser U, Gropp J. Effecrt of Lantharenol® on apparent phosphorus absorption from a conventional feline maintenance diet and a renal diet for cats. Proc Soc Nutr Physiol (2008) 17, in press.7 Data submitted for publication.
BVA’s Voice of the Veterinary Profession survey panel, which polls over 1,000 UK vets, highlighted that many vets support the higher welfare standards of British farming, with 9 out of 10 vets saying they would be more likely to buy food if it was labelled as British or locally sourced. Over three quarters of vets said that they would be more likely to buy free-range (77%) or food that carried a Farm Assurance Scheme label (over 50% for Red Tractor and RSPCA Assured; formerly known as Freedom Food).
BVA President Sean Wensley encouraged consumers to check labels as the warmer weather sees BBQs and picnics take centre stage in gatherings of families and friends. He said: "Animal welfare should be a paramount consideration whether we’re thinking about purchasing pets or the food we eat. For vets it’s a top priority that the animals we rear for food have a good life and a humane death.
"Vets are not alone in caring about where their food comes from. To support high standards of animal welfare, all of us can vote for good animal health and welfare through our thoughtful meat, fish, and dairy purchases and send a strong message to food producers and retailers this summer."
BVA’s Voice of the Veterinary Profession survey panel also revealed that 9 out of 10 vets would be less likely to buy meat or fish if it was labelled as not stunned prior to slaughter.
BVA is leading a campaign to end slaughter without pre-stunning for animal welfare reasons and calling for better labelling of food to help consumers make pro-animal welfare choices.
To find out more about BVA’s campaign to end non-stun slaughter, visit: http://www.bva.co.uk/News-campaigns-and-policy/Campaigns/An-end-to-non-stun-slaughter
Image: CC BY-SA 2.0 cyclonebill
The aim of the competition is to highlight top tips for pet owners and the benefits of building a den to help calm and reassure dogs during the fireworks festivities.
Practices that want to take part in the in the competition need to post pictures of their dens and waiting rooms on the Ceva Animal Health Facebook page in October. The winning practice will receive a £200 voucher and there are 10 runner up prizes of luxury chocolate hampers.
Abigail King, behaviour product manager at Ceva Animal Health, said: "Our hugely popular fireworks display competition encourages veterinary practices to create eye-catching and imaginative displays that help educate pet owners on what can be done at home to help calm and reassure pets with firework fears."
Ceva has a range of marketing materials for veterinary practices to use in the competition, including waiting room materials.
For further information, contact your Ceva territory manager.
The poster grades faeces from one (kickable) to six (most certainly not kickable).
James Kyffin, Veterinary Director at Protexin Veterinary said: "We believe that Poop Points offers pet owners a fun and engaging way to monitor their pet’s faeces."
That, surely, must win James the "Oxymoronic Veterinary Quote of the Year Award 2019".
More seriously, he went on to say: "It is important to raise awareness of alterations in animal’s faecal scores and ensure that this is communicated to their veterinary surgeon in an effective way."
Practices in the UK and Ireland can order their free poster on Protexin's website: https://www.protexinvet.com/pooppoints, or by emailing info@protexin.com.
Protexin will also be promoting digestive health advice on its website and social channels (@Protexin Veterinary on Facebook and Instagram), which practices can share and use.
The news comes only weeks after the RCVS announced conditional accreditation of the school's veterinary degree for a further year whilst further improvements could be made, having previously identified ‘wide-ranging concerns’.
The RCVS responded to the news with the following statement:
"We were very sorry to learn that Cambridge University’s Council of the School of Biological Sciences has decided to recommend to the University’s General Board that veterinary education at Cambridge should cease and, as ever, our first thoughts are with the students and staff team at the veterinary department, who will be affected directly by this news.
“As we reported on 25 November 2025, in light of the significant progress made by the vet department at Cambridge over the past 12 months towards meeting our accreditation standards, our Education Committee decided to grant conditional accreditation of the Cambridge veterinary degree programme for a further year to allow time for remaining improvements to be made.
“As stated, we appreciate the considerable efforts and hard work that the staff team at the vet department had put into rectifying many of the issues identified in the 2024 accreditation event, for taking on board the constructive advice that was given and working together to make many of the necessary improvements.'
“We had collaborated with the team within the vet department on putting together an action plan and timeline for meeting the 20 remaining recommendations, and we hoped that the department would continue on its current trajectory towards meeting our accreditation standards.
“The visitation panel noted the considerable efforts the department staff had made to make improvements in a relatively short timeframe, and the staff’s commitment to improving the remaining issues was clear. We also understood from discussions during the visitation that the department had the full and ongoing support of the School of Biological Sciences and wider University.
“In light of the School Council’s recent recommendation, however, we know that this will be a very upsetting and uncertain time for the vet department staff team and students, so we stand ready to offer as much support as we are able over the coming months.”
The BVA has also responded, it's President Dr. Rob Williams MRCVS saying: “When we met with senior leadership at Cambridge University back in June, we secured reassurances that they remained committed to the long-term future of the vet school.
"It’s therefore deeply concerning to hear that once again the future of Cambridge Vet School is in doubt.
"Working with students, alumni and staff, we’re seeking clarity on the situation and will make the case for its veterinary medicine degree course to continue."
A final decision will be made by the university's general board in January.
VetSurgeon member Shailen Jasani MA VetMB MRCVS DipACVECC has launched the Ralph site (theralphsite.com), a website offering support and advice to those coping with pet bereavement.
The site contains forums, downloadable advice sheets, a directory of crematoria and cemeteries, and offers owners the ability to create a memorial for their pet.
The Ralph site was named after Shailen's own cat, which died after a car accident in 2010. Shailen funded the setup of the site, and it is a not-for-proft.
Merial Animal Health has announced that it has purchased the the anti-inflammatory treatment for lameness in horses, Hyonate® (sodium hyaluronate), from Bayer.
Merial's equine marketing and technical manager, Louise Radford MRCVS said: "Hyonate is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection.
"The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism¹."
For more information telephone Customer Support on 0870 6000123 or contact your local Merial Equine Specialist.
Novartis Animal Health has issued the following statement concerning the supply of acepromazine (ACP) injectable in the UK:
"Recent upgrades to Novartis Animal Health’s manufacturing plant in the UK have resulted in the site becoming a worldwide centre of excellence for the production of bulk liquids. This upgrade has had an impact on the manufacture of ACP 2mg/ml and 10mg/ml injectable products, which will no longer be produced in the UK.
From January 2011, Novartis Animal Health will no longer be able to supply ACP Injection 2mg/ml or ACP Injection 10mg/ml to wholesalers. However, it is not Novartis’ intention to discontinue the supply of acepromazine injectable; in order to ensure consistency of supply to the UK market the company will be importing the Vetoquinol French product Calmivet.
Calmivet is a monovalent acepromazine injection licensed for use in dogs, cats and horses, available as a 5mg/ml injection, 50ml vial.
In order to obtain Calmivet from wholesalers, veterinarians will need to apply for a free of charge Special Import Certificate from the VMD. This can be completed on line at www.vmd.gov.uk.
It is anticipated that this situation will continue for at least the first 6 months of 2011, until an alternative manufacturing site is established. As soon as we have more information on the timelines this will be communicated.
A full communication including a prep room reminder poster and Calmivet product leaflet has been mailed to all UK practices.
Vetoquinol UK are not responsible for the distribution or technical support of this product, so any queries should be directed to Novartis Animal Health UK on 01276 694402.
The production and supply of ACP Tablets 10mg remains unaffected."
The product is marketed in a 10ml pack and has an expiry date of December 2017. The batch number is 6231-90D.
The 1ml syringe within the pack has 'Lbs' printed as the unit of measure instead of kg, which could lead to an incorrect dose being administered to dogs.
Any queries about returning this product should be addressed to:
Mr Ken Allen Qualified Person and Quality Advisor E-mail: ken.allen@norbrook.co.ukTelephone: + 02830 264435
Intervet/Schering-Plough Animal Health is to launch CICADA-Live, the second phase of its national initiative to monitor the awareness and regional prevalence of important diseases in cats, dogs and rabbits.
First launched in 2007 as a quarterly survey, the ground-breaking CICADA-Live project has now been developed to offer up-to-the minute data on infectious companion animal disease reports that can be updated and accessed by vet practices around the clock. The new scheme is now able to provide a real-time overview of companion animal infectious diseases being diagnosed in UK veterinary practices.
CICADA-Live is focusing on more than a dozen key infectious diseases of dogs, cats and rabbits. They include canine parvovirus, infectious canine hepatitis, canine distemper, leptospirosis, kennel cough, angiostrongylosis. For cats, CICADA-Live will monitor feline panleucopaenia, cat flu, feline leukaemia virus infections. For rabbits the focus will be on myxomatosis, rabbit viral haemorrhagic disease, E.cuniculi, and fly strike.
The service is officially launched on 1st June to coincide with Intervet/Schering-Plough Animal Health's National Vaccination Month 2009, and is open to all first-opinion UK companion animal veterinary practices.
The system's developer, John Helps, Veterinary Manager at Intervet/Schering-Plough Animal Health said: "Whereas our first edition of CICADA was useful in providing benchmarks so that seasonal and long term trends could be identified and communicated to both vets and pet owners, the further potential of a live on-line database is enormous in raising awareness of current pet disease risks to the public."
According to the company, there has been a lack of knowledge regarding the local and national incidence of small animal infectious diseases in the UK, and those sporadic reports that do occur are typically anecdotal and can prove hard to substantiate. It is feared that the lack of co-ordinated good quality information has potentially lead to pet owners being lulled into a false sense of security by a low awareness of disease risks.
John added: "Lack of data on the incidence and prevalence of even the most common infectious diseases has been an important issue faced by small animal practices reducing their ability to highlight these risks. A staggering lack of owner awareness to infectious disease threats in turn contributes to complacency among pet owners.
"Evidence suggests that some infectious diseases, such as parvovirus, may be on the increase in some areas and there continues to be a concern regarding the number of animals that remain unvaccinated.
"Not only will Cicada-Live provide the means for improving a gap in our collective knowledge but it will also prove invaluable in the promotion of good preventative healthcare.
"We have long believed that better epidemiological surveillance would an important tool in understanding trends in small animal infectious disease and with CICADA-Live, for the first time we have a tool to give us a better appreciation of what first opinion practices are currently seeing."
The CICADA-Live website, http://www.cicadasurvey.co.uk/, is simple to access and update. Registrations are limited to one per practice branch. A straightforward one-page survey format minimises the time investment, with no strict requirement to review written case records.
Once signed in, participating practices will be asked to complete the survey once every 6 months in order to grant continued access to maps and tables showing recent reports. In addition practices can set up e-mail alerts to give notification should disease reports be received in their area.
For further information about CICADA-Live from Intervet please contact Intervet /Schering-Plough Animal Health's Veterinary Support Group on 01908 685685. Or contact John.
Bovilis Rotavec Corona is used for the active immunisation of pregnant cows and heifers, 12-3 weeks pre-calving, to raise antibodies against rotavirus, coronavirus and E. coli F5 (K99). Calves gain protection by drinking the fortified colostrum from their vaccinated mothers.
The company says the new license indication will mean greater usage flexibility for UK cattle producers focusing on immunity-led prevention of infectious calf scours.
MSD ruminant veterinary adviser Dr Kat Baxter-Smith said: "On the old license, this vaccine needed to be used within eight hours of opening, so this will be a significant benefit-led change for suckler beef and dairy producers.
"For all-year-round calving dairy herds, for example – that may want to vaccinate successive pregnant dams on different days – it will make an opened bottle of vaccine last much longer. Those running batch calving herds with a long calving period should also benefit. We hope this will help reduce unnecessary wastage of the vaccine on farm and save farmers money.”
MSD says it will still be crucial to store the vaccine properly – upright and refrigerated (at 2-8°C) before and after broaching, and after first use. A broached vial will be able to be used once more during the next 28 days after the first vaccination event and then discarded. Vaccination equipment such as needles and syringes should be sterilized. Use of a multi-dose syringe to minimise vaccine contamination and excessive broaching is recommended.
The vaccine vials should still be shaken well before use. The injection should be made through an area of clean, dry skin with precautions taken against contamination.
Merial Animal Health has launched Certifect, a new POM flea and tick treatment for dogs.
The product was launched at a series of presentations by the survival and bushcraft expert, Ray Mears (pictured right) last week.
The connection between Ray Mears and a new flea and tick treatment for domestic dogs became clear as he recounted his experience of contracting Lyme Disease in the UK. Indeed, by the time he'd finished describing the crippling pain he'd suffered and the industrial quantities of morphine and tramadol he'd needed, most vets in the room were probably ready to place an order for a tonne of the new product.
But to dismiss it as just a polished marketing exercise would be wrong. According to the Health Protection Agency, cases of Lyme disease in people have risen from 296 in 2001 to 953 in 2010. It is thought that because the disease is difficult to diagnose, it is likely to be significantly under-reported. In addition, a study by Faith Smith from the University of Bristol last year found that of 3534 dogs examined, 810 (22.9%) were carrying at least one tick.
So, what about the new product? Well, it's essentially Frontline Combo (fipronil + the insect growth regulator, S-methoprine) but with added amitraz. At the low dose contained in Certifect, Merial explained that amitraz doesn't demonstrate acaricidal properties itself, but instead potentiates the effect of the fipronil and causes ticks to detach or fail to attach. It also causes ticks to move around more than they do normally, thereby exposing them to more fipronil.
Merial says the acaricidal effect of Certifect can be seen two hours after application, and that more than 90% of ticks are eliminated within 24 hours. After treatment, Certifect prevented 94.5% to 100% of ticks attaching until day 29, thereby reducing the risk of disease transmission. In terms of integrated flea control, think Frontline Combo.
Certifect can be used on pregnant and lactating bitches, on puppies from 8 weeks weighing more than 2kg, and on dogs which live in households with cats.
The study was the first to use prospectively collected data to estimate the prevalence of and risk factors for gingivitis in a cohort of domestic cats, using data from 860 cats aged up to six years enrolled in the Bristol Cats Study. Gingivitis was found to be a common condition in cats aged up to six years, with prevalence increasing with age, from 24.5% in cats less than 12 months old, up to 56.3% in cats between five and six years old. Odds of gingivitis in cats aged three to four years were higher in cats fed a wet only or mixed wet/dry diet compared to those on a dry only diet; cats not reported to hunt prey compared to reported hunters; cats reported to dribble whilst being stroked at age six months compared to reported non-dribblers; and cats with orange variants in their coat colour compared to non-orange cats. Sex was not found to be a risk factor for gingivitis (Ed's note: what a relief). Jess Williams, lead author of the study, said: “Periodontal disease is one of the most common conditions in cats, potentially causing issues with eating and behaviours like grooming.
"Our study showed that even young cats may have signs of gingivitis, so it is important to discuss and monitor dental health regularly and early on in a cat’s life, especially for those cats who may be more at risk.”
The study was funded by BSAVA PetSavers.
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13737
Rodney (pictured right) has spent the last 26 years practising in the USA, latterly at the California-based Advanced Veterinary Specialists & Animal Specialty Group.
After growing up in Zimbabwe and graduating from the University of Pretoria in South Africa in 1985, he moved to London, where he became an MRCVS, and thence to the USA.
He undertook a small animal internship at the Animal Medical Centre in Manhattan, before moving to the Ohio State University for his residency in medical oncology in 1989. He achieved Board Certification in medical oncology in 1994 and in radiation oncology in 2000.
Rodney specialises in the application of multi-modality therapy protocols for the treatment of cancer in animals, and has conducted research on the phenomenon of multi-drug resistance, mast cell tumour and oral melanoma.
He said: "Thirty-something years on, I have come back to the UK as a specialist, where I started as a GP. Living in the UK also brings me much closer to my family, which is very important to me.
"Over the years, veterinary practice in the USA has changed significantly, where it has become more corporate and less personal. I enjoy being part of a new group where typically it is much closer, friendlier and more like a family."
Rodney now plans to oversee the development of a comprehensive oncology department to include chemotherapy, surgery, radiation therapy, immune-therapy and molecular targeted therapy.
He said his work at Paragon will focus on educating referring vets and clients about what is possible in the oncology field.
He said: "My job will be about increasing the level of knowledge, both of owners and general practitioners, of how we treat cancer in animals.
"It can be a scary disease and the first door an owner needs to step through, is understanding that treating a pet is very different to treating a human.
"The intention in humans is usually to cure but with pets, it is more about providing a good quality of life for as long as possible.
"There can be a fear of cancer therapy but if you stick to the protocols, it is no different to treating any other chronic incurable diseases. We use the safest methods with an abundance of caution and try to make sure that the treatment is not worse than the disease.
"It’s about internal training too, from reception right up to nurses and interns, looking at what we do and how we do it, to optimize the quality of life of the pet and their owners.
"I would like to see an oncology department that considers the emotional, financial, time and patient concerns of the owners, so they feel their commitment to cancer treatment for their pet is not a commitment to putting their pet or themselves through a difficult time."
Dr Bohnen faced two charges. The first was that in March 2017, she failed to attend to Belle, a Cavalier King Charles Spaniel, in order to provide appropriate and adequate care including: assisting Belle with urination, monitoring her with a view to considering alternative treatment options, and monitoring her with a view to providing her owners with an update on her condition.
The second charge was that Dr Bohnen later claimed dishonestly that she had attended to the animal, both to the owners, in clinical records hospital records, in a note provided to colleagues and during internal disciplinary proceedings held at her practice.
At the outset of the hearing the Committee considered an application from Dr Bohnen for the hearing to be postponed as she was now based in her home country of South Africa, and said she could not apply for a visa to return to the UK until later in the year and internet access in her location was poor.
However, the Committee found that the RCVS had properly served the notice of inquiry to Dr Bohnen in accordance with the current rules, that she had had sufficient time and opportunity to apply for a visa since receiving the notice and that, in any case, she could remotely ‘attend’ the hearing via Skype or telephone if necessary by travelling to somewhere that did have adequate internet connectivity, and so it refused the application.
The Disciplinary Committee then considered the facts of the case and heard evidence from the owners of Belle, the clinical director of the practice that Dr Bohnen worked in at the relevant time and a veterinary nurse, who was a student doing her training at the practice during the time of the events in question.
Having considered all of the evidence, the Committee dismissed the parts of the first charge relating to considering alternative treatment options and updating the owners in relation to Belle’s condition. They did, however, find the charge proven in relation to Dr Bohnen failing to assist Belle with urination.
The Committee found all aspects of the second charge proven in its entirety after Dr Bohnen admitted in advance of the hearing, that her representations were false and misleading.
The Committee then went on to consider whether the second charge and the aspects of the first charge that were found proven amounted to serious professional misconduct both individually and cumulatively.
The Committee considered that Dr Bohnen’s conduct in failing to assist Belle with urination, whilst falling below the standard to be expected of a reasonably competent veterinary surgeon, did not amount to serious professional misconduct.
The Committee did however find that Dr Bohnen’s conduct with regards to the second charge constituted serious professional misconduct.
Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considers that the respondent’s dishonesty was the prime aggravating factor in this case. Although overall it could be regarded as a single incident, the Committee has found that it involved the fabrication of a number of notes and clinical records in the immediate aftermath of the death of the dog, but, thereafter, the respondent continued to deny the falsity of the fabricated records that she had created up to and until the conclusion of her interview by the practice on 30 March 2017.
"During that time, the respondent had contacted the alarm company responsible for the security of the premises of the practice, to enquire whether the security system would record the times of the alarm being switched on and off. This indicated that the respondent’s dishonesty continued over a significant period of time, and that her persistence in sticking to her story became premeditated. In other words, the respondent’s conduct over this time indicated a clear attempt to deceive."
Regarding the sanction for Dr Bohnen, the Committee considered that the principle aggravating factors in the case were serious dishonesty towards both her colleagues and the owners of the dog and involved clear breaches of the Code of Professional Conduct. By way of mitigation, the Committee noted that Dr Bohnen is of previous good character with no other professional findings against her and that she had demonstrated some insight into her behaviour and had admitted being dishonest and misleading prior to the hearing.
Summing up, Professor Barr said: "Because of the seriousness of this case, the Committee did not consider that it was appropriate to postpone judgement, take no further action, or to administer a reprimand and warning as to future conduct. The Committee considered that the respondent’s conduct, involving significant and admitted dishonesty over a period of time, required a significant penalty, in order to protect the welfare of animals and to serve the public interest.
"Accordingly, the Committee has decided to direct that the respondent’s registration be suspended for a period of nine months."
Dr Bohnen has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.
Whilst you're here, take a moment to see our latest job opportunities for vets.
The new Veterinary HPM Adult Neutered Wet with Salmon (a lifestage diet) and Urology Cat Wet (a clinical diet) have a high-protein low-carbohydrate formulation and a high share of animal protein.
Virbac points to studies which show that FLUTD is diagnosed in 8% of cats seen by vets for non-routine appointments1 and that there is a 51% risk of recurrence within one year of the initial diagnosis2.
Dr Rémi Mandray DMV MRCVS, Product Manager at Virbac, said: "Feline specialists recognise the importance of nutrition and water intake in the management of FLUTD, so we are delighted to be able to add two high quality wet diets to the Veterinary HPM range and therefore offer advanced nutritional solutions to such an important health issue."
Virbac says that both diets have high levels of animal protein to stimulate water intake, increase the volume of urine and stabilise the pH for a healthy urinary system.
The lifestage diets include supplements to limit phosphorus excretion in the urine for improved prevention of struvite crystal formation.
The company also says the Urology diets in the clinical range meet the PARNUT requirements for dissolution and prevention of struvite stones or crystals, and prevention of oxalate formation.
Virbac claims the new chunks in gravy wet diets naturally increase water intake by up to 50%, due to their high water content.
Dry and wets can be fed together as part of a mixed nutritional programme, to meet pet owner preferences identified in Virbac's market research: 60% of cat owners use wet food, mostly mixed with kibbles4.
For more information, contact your Virbac Territory Manager.
References
The clinic is led by Sebastien Behr MRCVS, an RCVS Specialist in Neurology. Patients will benefit from access to the referral centre's MRI scanner and its specialist imaging, anaesthesia and neurology teams.
Dr Behr said: "We are very excited to have launched this specialist clinic. Following detailed consultations with pet owners, the animals will be treated to the very highest level and bespoke care designed for each patient."
The practice is offering a fixed price package for routine diagnostic procedures.
For more information, visit www.willows.uk.net or contact the neurology team on 0121 721 7070.
Vikaly is indicated for the nutritional and medical management of chronic kidney disease in adult and senior cats with proteinuria, from IRIS stage 2.
The new diet delivers the same therapeutic dosage as benazepril tablets (0.5–1 mg/kg bodyweight/day).
Nutrition-wise, Vikaly is low phosphorus (0.5% as fed), has reduced protein (30% as fed), contains omega-3 fatty acids (1.2%, including 0.6% EPA & DHA) and offers high metabolisable energy (416 kcal/100g).
Virbac highlights data showing that CKD remains the leading cause of mortality in cats over five years old and affects up to 40% of feline patients over the age of ten1,2.
The company says administering daily treatment is recognised as a major issue for CKD cat owners with 45% of owners not administering treatment daily as they should and 51% of owners citing administration difficulties as the reason why3.
This new product eliminates the need to administer medication separately, which could completely transform treatment compliance, removing the risk of missed doses and reducing stress for both cats and their owners.
Virbac says that due to the pharmacokinetic profile of benazepril, which is incorporated into the kibble, at an equivalent dose Vikaly displays greater ACE inhibition than benazepril tablets4.
The rate of food consumption also does not affect plasma Benazeprilat levels, ensuring consistent treatment efficacy regardless of the cat’s feeding behaviour5.
Virbac says that in practice, this means that even if the cat being treated consumes less than 50% of their daily ration, efficacy is maintained with ACE activity similar to that of benazepril tablets.
Benazepril has a wide therapeutic margin, tolerated to 20x the minimum effective dose (10mg/kg) for 52 weeks, with the first signs of toxicity being reduced erythrocytes counts & ovary/oviduct weights6.
Virbac says that with Vikaly, these levels cannot be reached because the active ingredient is contained in food, which would require a cat to consume more than 10 times their daily ration.
Vikaly is presented in a 1.5kg bag, which equates to a 30 day supply for a 4.5kg cat with normal bodyweight.
It can be fed alongside wet food, providing that the cat consumes at least 50% of their daily ration before being given the wet food.
The daily ration can also be administered in several smaller meals throughout the day, to accommodate the individual preferences of the cat and to promote consistent food intake.
Vikaly is a prescription diet.
The Government says that contracts have been secured with Brittany Ferries and DFDS to run ferries into and out of Poole, Portsmouth, Plymouth, Immingham and Felixstowe, thereby relieving pressure on the Dover straights.
Critical goods have been identified as those essential for the preservation of human and animal welfare, including all veterinary medicines authorised under the Veterinary Medicines Regulation 2013, including finished and un-finished products, and Active Pharmaceutical Ingredients (for import and export).
Critical goods also include unauthorised medicines permitted for import under the Veterinary Medicines Directorate’s Special Import Scheme (for import only).
Photo: Shutterstock/Peter Hermes Furian
Dechra Veterinary Products has launched a 5 ml bottle of Comfortan (methadone), its titratable analgesia for cats and dogs.
The new sized bottle of Comfortan, designed for use with animals in, or about to experience, moderate to severe pain, is now available from veterinary wholesalers.
Dechra Brand Manager Craig Sankey said: “The new 5ml bottle is a great size for practices which would like to introduce Comfortan into their practice protocols, allowing them to do so in a cost-effective way.
“The availability of a smaller bottle will also be a benefit to practices which due to different surgical needs, currently only use Comfortan in a small number of cases. They will then be able to simply and easily trade up to the 10 ml bottle once they start to use Comfortan on more cases.”
The 5 ml has also been introduced in response to demand from branch practices which had been transferring 10ml bottles between sites and for cat-focused practices which use smaller volumes of the product.